- Incannex Healthcare (IHL) has filed a provisional patent application for the use of IHL-42X for the treatment of obstructive sleep apnoea (OSA)
- Incannex says it intends to use the application to pursue further patent protection for its clinical program for the drug, dubbing the move “consistent” with its ongoing commercial strategy
- The new patent joins Incannex’s previous filing as part of the IHL-42X development program
- Meanwhile, Incannex also engaged Dr Brad Edwards, Associate Professor of Physiology at Monash University, to further assess the polysomnography data from its phase two clinical trial that investigated the effect of IHL-42X on OSA
- Incannex Healthcare last traded at 20.5 cents at 11:00 am AEDT
Incannex Healthcare (IHL) has expanded its intellectual property position for the use of IHL-42X to treat obstructive sleep apnoea (OSA).
Obstructive sleep apnoea is the most common sleep-related breathing disorder, which sees a person’s upper airway narrow during sleep. This can interfere with breathing and decreases oxygen uptake, with the potential to lead to cardiovascular disease, heart attacks, depression and hypertension.
The company filed a provisional patent application, which Incannex said it intends to use to pursue further patent protection for its clinical program for the drug.
IHL-42X was designed to combine two drugs – tetrahydrocannabinol (THC) and acetazolamide – with therapeutic effects on OSA that act via different mechanisms. The company previously found the two drugs act “synergistically” to reduce the Apnea Hypopnea Index (AHI) in patients with OSA.
The company said the move is consistent with its ongoing commercial strategy to accrue a patent position across the development, manufacture, and use of its drug candidates.
The new patent joins Incannex’s previous filing as part of the IHL-42X development program.
“Incannex works closely with its patent attorneys to build upon its competitive position through the ongoing development of intellectual property assets,” Incannex CEO and Managing Director Joel Latham said.
“Our intention is to build patent families around our drug candidates as we learn more about them through our research and development programs undertaken by our dedicated scientific teams”.
Meanwhile, Incannex also engaged Dr Brad Edwards, Associate Professor of Physiology at Monash University, to further assess the polysomnography data from its phase two clinical trial that investigated the effect of IHL-42X on OSA.
Incannex Healthcare last traded at 20.5 cents at 11:00 am AEDT.